# Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

> **NCT04678830** · PHASE2 · COMPLETED · sponsor: **CytoDyn, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Coronavirus Disease 2019

## Interventions

- **DRUG:** Placebos
- **DRUG:** Leronlimab (700mg)

## Key facts

- **NCT ID:** NCT04678830
- **Lead sponsor:** CytoDyn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-01
- **Primary completion:** 2021-06-05
- **Final completion:** 2021-07-08
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2024-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04678830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04678830, "Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04678830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*